Results 11 to 20 of about 216,439 (378)
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. [PDF]
Blood, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...Bin Zhang, S. Chu, Puneet Agarwal, V. Campbell, L. Hopcroft, H. Jørgensen, A. Lin, K. Gaal, T. Holyoake, R. Bhatia +9 moresemanticscholar +3 more sourcesMtss1 is a critical epigenetically regulated tumor suppressor in CML [PDF]
Leukemia, 2016 Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...M. Schemionek, O. Herrmann, M. Reher, Nicolas Chatain, Claudia Schubert, Ivan G. Costa, Sonja Hänzelmann, Eduardo G. Gusmao, S. Kintsler, T. Braunschweig, A. Hamilton, G. Helgason, M. Copland, Albrecht Schwab, Carsten Müller-Tidow, Shaoguang Li, T. Holyoake, T. Brümmendorf, S. Koschmieder +18 moresemanticscholar +3 more sourcesBCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]
, 2012 MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa +53 morecore +1 more sourceThe vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1-CD44 axis. [PDF]
, 2020 The endosteal bone marrow niche and vascular endothelial cells provide sanctuaries for leukemic cells. In murine chronic myeloid leukemia (CML) CD44 on leukemia cells and E-selectin on bone marrow endothelium are essential mediators for the engraftment ...Aggoune, D., Godavarthy, P., Hayduk, N., Herkt, S., Krause, D., Kumar, R., Lausen, J., Lucas, T., Manavski, Y., Müller, M., Oehler, V., Oellerich, T., Pan, K., Pereira, R., Saussele, S., Voutsinas, J., Weissenberger, E., Wu, Q. +17 morecore +2 more sourcesUptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]
, 2010 Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.Alison M. Michie, Baillie, Bellodi, Bhatia, Bocchia, Brown, Claire Crossan, Collins, Copland, Davies, Deckelbaum, Dirks, Firestone, Gal, Gavin W. Halbert, Ghalaut, Graham, Halbert, Hamilton, Hamilton, Hatziieremia, Hayavi, Hayavi, Heather G. Jørgensen, Ho, Hochhaus, Holyoake, Hughes, Jordanides, Jorgensen, Jorgensen, Kramer, Linda Scobie, Moira A. Elliott, Nikanjam, Nikanjam, Owens, Peixun Zhou, Rousselot, Sophia Hatziieremia, Stingl, Tatidis, Tessa L. Holyoake, Vitols, Weisberg, White, White, WilsonRawls +47 morecore +1 more sourceChronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]
, 2012 Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White +61 morecore +1 more sourceCombined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia [PDF]
, 2016 Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer
progression, biomarker identification and the design of individualized therapies.Brehme, Marc, Brümmendorf, Tim H,, Copland, Mhairi, Koschmieder, Steffen, Montazeri, Maryam, Oehler, Vivian G., Radich, Jerald P., Schuppert, Andreas +7 morecore +1 more sourceProspective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study.
Blood, 2019 In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is considered the gold standard for BCR-ABL1 KD mutation screening, next ...S. Soverini, Luana Bavaro, C. De Benedittis, M. Martelli, A. Iurlo, N. Orofino, S. Sica, F. Sorà, F. Lunghi, F. Ciceri, S. Galimberti, C. Baratè, M. Bonifacio, L. Scaffidi, F. Castagnetti, G. Gugliotta, F. Albano, A. R. Russo Rossi, F. Stagno, F. Di Raimondo, M. D'adda, E. di Bona, E. Abruzzese, G. Binotto, R. Sancetta, M. Salvucci, I. Capodanno, M. Girasoli, S. Coluzzi, I. Attolico, C. Musolino, E. Calistri, M. Annunziata, M. Bocchia, S. Stella, A. Serra, Santa Errichiello, G. Saglio, F. Pane, P. Vigneri, F. Mignone, M. Laginestra, S. Pileri, A. Percesepe, E. Tenti, G. Rosti, M. Baccarani, M. Cavo, G. Martinelli +48 moresemanticscholar +1 more sourceAssessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Leukemia, 2017 Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN ...Rüdiger Hehlmann, Michael Lauseker, Susanne Saussele, Markus Pfirrmann, S. Krause, Kolb Hj, Andreas Neubauer, D. Hossfeld, C. Nerl, A. Gratwohl, G. Baerlocher, D. Heim, T. Brümmendorf, A. Fabarius, C. Haferlach, B. Schlegelberger, M. Müller, S. Jeromin, Ulrike Proetel, K. Kohlbrenner, A. Voskanyan, S. Rinaldetti, W. Seifarth, B. Spiess, Leopold Balleisen, M. Goebeler, Mathias Hänel, A. Ho, J. Dengler, C. Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, M. Kneba, Frank Stegelmann, C. Köhne, H. Lindemann, C. Waller, Michael Pfreundschuh, K. Spiekermann, We Berdel, Lutz P. Müller, Matthias Edinger, J. Mayer, D. Beelen, M. Bentz, Hartmut Link, B. Hertenstein, R. Fuchs, M. Wernli, F. Schlegel, R. Schlag, M. D. Wit, L. Trümper, H. Hebart, M. Hahn, J. Thomalla, C. Scheid, P. Schafhausen, Walter Verbeek, M. Eckart, W. Gassmann, A. Pezzutto, Michael Schenk, P. Brossart, T. Geer, S. Bildat, E. Schäfer, A. Hochhaus, J. Hasford +69 moresemanticscholar +1 more sourceCOVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
Blood, 2020
Background
Comorbid ...D. Réa, M. Mauro, J. Cortes, Q. Jiang, K. Pagnano, M. Ongondi, C. Kok, N. Evans, T. Hughes, International Cml Foundation +9 moresemanticscholar +1 more source
